Mathata a ho tšoenyeha ke lefu le atileng haholo la kelello US, le amang batho ba baholo ba ka bang limilione tse 40 selemo se seng le se seng, 'me ho sa tsotellehe bongata ba meriana e thibelang ho tšoenyeha e teng, ho hanyetsa phekolo ho etsahala ho hoo e ka bang 30% ea bakuli. Mathata a ho tšoenyeha a na le phello e kholo ea moruo tsamaisong ea tlhokomelo ea bophelo ea US, e bitsang chelete e pakeng tsa $ 42.3 le $ 46.6 limilione tse likete selemo le selemo, ho bolelang hore ho bohlokoa ho fumana mekhoa e meng ea phekolo. Ka lehlohonolo, lipatlisiso tse ncha li senola hore psychedelics e ka ba karabo. Liphetho tsa liteko tsa tleliniki li bonts'a hore psilocybin, psychedelic e matla, e na le litlamorao ho bakuli ba nang le khatello ea maikutlo mme e sebetsa ho feta escitalopram. Ha e le hantle, ena ke e ’ngoe ea liphuputso tse ngata tse atlehileng tse amanang le tšebeliso ea mafu a kelello e le phekolo ea mafu a kelello.
Cybin Inc e tsepamisitse maikutlo ho ntlafatseng li-psychedelics ho tsa kalafo ka ho rala sethala sa ho sibolla lithethefatsi, litsamaiso tse ncha tsa phepelo ea lithethefatsi, mekhoa e mecha ea ho qapa le mekhoa ea kalafo bakeng sa mathata a bophelo bo botle ba kelello.
Ka la 13 Mmesa, Cybin o ile a phatlalatsa lintlha tse ntle tsa CYB004 tse tsoang phuputsong ea pharmacokinetic e hlahlobang molek'hule oa eona oa deuterated dimethyltryptamine (DMT), CYB004, e tsamaisoang ka ho hema. Haholo-holo, CYB004 e hulelitsoeng e bonts'itse melemo e kholo ho feta DMT e kenang ka har'a methapo le ho hema, ho kenyelletsa le nako e telele ea ketso le bioavailability e ntlafetseng. Boithuto bo boetse bo bonts'itse hore CYB004 e hahelletsoeng e bile le ts'ebetso e ts'oanang ea phello le profil ea litekanyetso ho IV DMT. Lintlha tsena li ka ts'ehetsa bokhoni ba ho hema e le mokhoa o sebetsang le o laoloang hantle oa ho fana ka li-psychedelics tsa phekolo. Cybin hajoale e ntse e hlahisa CYB004 bakeng sa kalafo ea mathata a ho tšoenyeha. Khamphani e lebelletse ho kenya faele ea taolo bakeng sa boithuto ba lifofane kotareng ea bobeli ea 2022 le ho qala boithuto ba lifofane kotareng ea boraro.
"Lithutong tse ngata, DMT e bonts'itse e le setsebi sa kelello se ts'episang le se sebetsang bakeng sa kalafo ea litaba tsa bophelo bo botle ba kelello. Leha ho le joalo, litla-morao tse tsejoang joalo ka ho ferekana kelellong le ho tšoenyeha le mokhoa oa tsamaiso li sitisitse ho sebelisoa le ho fumaneha ha eona khale. CYB004 ka ho hema e ka rarolla mathata ana 'me qetellong ea tšehetsa tsela ea bongaka ea ho ea pele bakeng sa phekolo ena ea bohlokoa. E le karolo ea morero oa Cybin ka kakaretso oa ho theha phekolo e sireletsehileng le e sebetsang ea psychedelic-based therapeutics, inhaled CYB004 e ntse e ntlafatsoa ho hlōla mefokolo ea IV DMT le ho ba khetho ea bohlokoa ea phekolo bakeng sa mathata a ho tšoenyeha ho bakuli le lingaka, "ho boletse Doug Drysdale, Mookameli oa Cybin. .
Ka la 8 Mmesa, Cybin o phatlalalitse phatlalatso ea kopo ea machaba ea patent e akaretsang mekhoa ea phepelo ea ho hema bakeng sa limolek'hule tse ngata tsa psychedelic, e matlafatsang boemo ba Cybin's intellectual property (IP). Kopo ea PCT e tla lumella Cybin ho batla tšireletso ea IP bakeng sa mefuta e mengata ea limolek'hule tsa psychedelic tse ntseng li etsoa lipatlisiso le ho ntlafatsoa ke k'hamphani hammoho le limolek'hule tse ling tsa psychedelic tse ka 'nang tsa ntlafatsoa nakong e tlang.
"Phatlalatso ea kopo ena ea patent ea PCT e bontša boitlamo ba rona bo tsoelang pele ba ho fumana le ho hlahisa mekhoa e mecha ea phekolo e thehiloeng ho psychedelic, ntle le ho khetholla le ho kopanya mekhoa e ka 'nang ea ntlafatsoa le e laoloang hantle ea ho fana ka litšebeletso le batho bana ba kliniki," ho boletse Doug Drysdale. "Ho feta moo, tsoelo-pele ea rona ea ho boloka IP bakeng sa mekhoa e ikhethang ea ho fana ka psychedelic e lumellana ka matla 'me e tšehetsa lenaneo la rona la liphaephe la CYB004 la deuterated DMT ka ho inhalation, e reretsoeng ho hlōla tse ling tsa mathata a tsejoang a DMT ea molomo le ea IV."
Cybin e phatlalalitse ka la 31 Hlakubele hore boithuto ba eona bo tšehelitsoeng bo sebelisa theknoloji ea Kernel Flow e entse ketelo ea eona ea pele ea boithuto. Sepheo se seholo sa phuputso ke ho hlahloba phihlelo ea monkakarolo ea apereng Kernel Flow ha a ntse a le boemong bo fetohileng ba kelello ka mor'a tsamaiso ea ketamine. Barupeluoa ba tla fumana tekanyo e tlase ea ketamine kapa placebo ha ba ntse ba roetse li-headset tsa Flow, tse nang le li-sensors tsa hi-tech ho hatisa ts'ebetso ea boko 'me ba tla tlaleha phihlelo ea bona ba sebelisa lipotso tse hlophisitsoeng le litlhahlobo tse tiisitsoeng nakong ea maeto a boithuto le ho latela. Thuto ea libeke tse 'nè e tla boela e hlahlobe tšebetso ea boko pele le ka mor'a ho fana ka li-agent tsa thuto - ketamine ea tekanyo e tlaase kapa placebo.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- The company expects to file a regulatory filing for a pilot study in the second quarter of 2022 and to initiate the pilot study in the third quarter.
- As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians,”.
- The main objective of the study is to evaluate a participant’s experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine.
